Ernest C. Borden, MD; David Parkinson, MD
Borden EC, Parkinson D. Interferons: Effectiveness, Toxicities, and Costs. Ann Intern Med. 1996;125:614-615. doi: 10.7326/0003-4819-125-7-199610010-00012
Download citation file:
Published: Ann Intern Med. 1996;125(7):614-615.
Phase I, II, and III trials that defined the therapeutic effectiveness of interferons for neoplastic, viral, and immunologic diseases have helped improve the quantity and quality of life for thousands of patients. Hematologic malignant conditions have been particularly responsive to interferon treatment, but solid tumors have also been treated successfully. Interferon treatment has also decreased the duration of the symptom phases in viral diseases of DNA and RNA virus origin and have decreased the number and duration of complications of these diseases. As the use of interferons has become more widespread and duration of treatment has increased, these agents themselves have been identified as potent modifiers of biological response. Like glucocorticoids, interferons result in unwanted side effects when given in pharmacologic doses.
Learn more about subscription options.
Register Now for a free account.
Endocrine and Metabolism, Hematology/Oncology, Infectious Disease, Neurology, Thyroid Disorders.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only